Biotech no lifesaver,as five pull the plug

Sun Oct 1, 2006

Managers hope a new FDA chief and more drug approvals will provide a much-needed turnaround

Drug and biotech companies may be on the hunt for lifesaving cures, but until very recently, they have been bitter medicine for hedge fund managers. In fact, at least five biotech-driven hedge funds have pulled the plug this year, the latest being Caxton Health Care Trading, a $417 million fund that decided to close its doors last month after netting 1.46% annual returns since it opened nearly two years ago.

Reflecting the malaise of other equity investors, many biotech funds struggled through the first half but rebounded in August, giving a composite list compiled by Absolute Return a 7.04% showing year-to-date, slightly besting Absolute Return's Composite Index, which rose 6.52% during the same time. But in July, biotech was trailing Absolute Return's Composite by more than 2%, so the sudden reversal has emboldened some...

ISSN: 2151-1845 / CDC10004H


The full contents of this article are available to active AR subscribers and trialists only.

To continue reading please,
take a free trialsubscribe or log in to AR.


Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.

Subscribe now

Popular Searches on HFI